38 organizations representing patients and people with disabilities strongly urged the Maryland Prescription Drug Affordability Board (PDAB) to prioritize the perspectives of people whose care may be impacted by your decisions as it works to finalize a Plan of Action for Implementing the Process for Setting Upper Payment Limits
|
In a letter to the Institute for Clinical and Economic Review, PIPC submitted comments on ICER's assessment of treatments for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
On August 2, the Partnership to Improve Patient Care (PIPC) submitted a comment letter to Reps. Diana DeGette (D-CO) and Larry Bucshon (R-IN) on their recent request for information (RFI) on advancing 21st Century Cures policies.
Nearly 60 organizations and advocates representing the patient and disability communities joined PIPC's comment letter on the Centers for Medicare and Medicaid Services' (CMS) guidance implementing the Medicare Drug Price Negotiation Program.
On June 10, PIPC submitted a comment letter on the Institute for Clinical and Economic Review’s (ICER) assessment of anemia in myelodysplastic syndrome (MDS).
On May 23, PIPC submitted a comment letter to the Colorado Prescription Drug Affordability Board (PDAB) on the Board's ongoing process for affordability reviews and establishment of upper payment limits.
PIPC submitted a letter to the Oregon Prescription Drug Affordability Board (PDAB) on the Board's ongoing affordability review activities.
On May 13, PIPC submitted a comment letter to the Maryland Prescription Drug Affordability Board (PDAB) on the Board's ongoing Cost Review Study process.
On May 7, PIPC submitted comments on the Institute for Clinical and Economic Review's (ICER) assessment of chronic obstructive pulmonary disease (COPD).
|
